PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AstraZeneca and Novavax say their vaccines are effective against Omicron

WHO officials remain cautious about claiming Omicron as a milder variant of the COVID-19 virus.

Vaccine manufacturers AstraZeneca and Novavax have said that their respective shots provide protection against the latest COVID-19 variant Omicron. This comes in the wake of UK data which has suggested that Omicron causes fewer hospitalisations than the Delta variant.

Novavax Inc has said that early data showed its vaccine – authorised for use this week by EU regulators and the World Health Organization (WHO), but yet to be approved in the US – generated an immune response against Omicron.

The same day, AstraZeneca announced that a three-course dose of its COVID-19 vaccine offered protection against the variant and cited data from an Oxford University lab study. The study on the company’s vaccine, Vaxzevria, demonstrated that following a three-dose course, neutralising levels against Omicron were similar to those against Delta after two doses.

Despite this promising data, WHO officials have emphasised that there is not yet enough evidence to support the claim that Omicron is a mild variant. The technical lead on COVID-19, Maria van Kerkhove, expressed in a briefing in Geneva that the data on Omicron was still “messy”.

Omicron is now the dominant variant in the US and is rapidly becoming more dominant in most of western Europe. In Britain, Omicron has caused daily infections to soar beyond 100,000.

Whilst COVID-19 hospitalisations and deaths in the UK have been more gradual, Raghib Ali, a senior clinical research associate at the University of Cambridge, has warned that even a small proportion of hospitalisations could be enough to overwhelm the healthcare system. However, Ali expressed that the UK data was encouraging and “may help justify the government’s decision not to expand restrictions on social gathering over Christmas in England”.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026